Court Ruling Pressures Stem Cell Stocks

Following Monday's ruling in the Federal District Court for Washington, D.C., to block federal funding for research that uses human embryonic stem cells, companies researching and developing medical techniques involving stem cells saw shares tumble down today across the board.

FDA OKs First Trial of Stem Cells to Heal Spine Injuries

The Food and Drug Administration cleared the way on Friday for California biotech firm Geron to begin human clinical trials of its experimental embryonic stem cell-based therapy to heal spinal cord injuries in paraplegic patients.

Pfizer Invests in Stem Cell Therapy

Long an old-line drug company, Pfizer is looking increasingly like a new biotech these days, especially after licensing a stem cell therapy. Athersys' MultiStem is a therapy that consists of a special class of stem cells obtained from the bone marrow of healthy, adult donors to treat inflammatory bowel disease.